Welcome to: Rimonabant Information Source (generic accomplia rimonabant goldpharma)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Weight loss appetite suppressant Drugs Unit Weight once won is not easy to lose and this fact is by millions of people worldwide suffering from obesity and its related health issues. Traditional methods of weight loss such as diet and physical help, but only to a certain extent. If your line of overweight to obesity, you need the help of medication to reduce weight. Appetite suppressant drugs are currently one of the most popular weight loss medication around. Weight loss with appetite suppressants is easy if you do not have to limit your natural feelings for food. On the contrary, the medicine is for you by cutting your urge to eat. Most appetite suppressant drugs work the same way, by leading your brains a signal that you are not hungry.

Rimonabant Pricelist

Please wait while we load the price list
Acomplia (rimonabant) – Anti-obesity medication for safe and effective weight loss Acomplia is an anti-obesity drug manufactured by Sanofi Aventis. It is used to aid obese and overweight patients with associated risk factors of high diabetes or high cholesterol lose weight. Acomplia is approved for use within the European Union and has been available to patients in the UK since June 2006. This anti-obesity medicine is yet to be approved by the FDA for the US. About Acomplia If you want to know how Acomplia helps in weight loss, the following explanation will help you out. Acomplia is an anti-obesity medicine works by blocking receptors called cannabinoid-1 receptors (CB1). These receptors are found in several parts of the body such as in the brain, fat tissue, digestive system, liver, and muscles.

GYN. NEWS, Jan. 1, 2005, p. 36). Armed with data from more than 6,600 overweight and obese participants in these two trials plus two Sanofi-Aventis-sponsored 1-year phase III trials, the company plans to file before midyear for Food and Drug Administration and European Commission approval of rimonabant 20 mg/day for weight loss, a spokesman told this newspaper. Simultaneously, Sanofi-Aventis will file for a smoking cessation indication, the subject of another extensive phase III rimonabant clinical trials program. RIO-Europe was a randomized, double-blind, placebo-controlled study involving 1,507 overweight or obese patients with a mean baseline body mass index of 37 kg/[m.sup. 2] and a mean age of 45 years. As is typical in weight loss trials, 80% were women. Participants were strongly encouraged by dietitians and counselors to adopt a 600-kcal/day-deficit diet and increase their physical activity.